vs
Side-by-side financial comparison of GEN Restaurant Group, Inc. (GENK) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $49.7M, roughly 1.7× GEN Restaurant Group, Inc.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -9.0%). GEN Restaurant Group, Inc. produced more free cash flow last quarter ($-5.6M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -1.0%).
Gen Korean BBQ is an American chain of all-you-can-eat Korean barbecue restaurants mainly concentrated around the Western U.S. It opened in 2011, and has since grown to 43 locations as of 2024.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
GENK vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $49.7M | $86.8M |
| Net Profit | $-1.9M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | -24.5% | -84.7% |
| Net Margin | -3.8% | — |
| Revenue YoY | -9.0% | 17.7% |
| Net Profit YoY | -821.4% | — |
| EPS (diluted) | $-0.37 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $49.7M | $86.8M | ||
| Q3 25 | $50.4M | $67.5M | ||
| Q2 25 | $55.0M | $60.0M | ||
| Q1 25 | $57.3M | $49.3M | ||
| Q4 24 | $54.7M | $73.7M | ||
| Q3 24 | $49.1M | $58.6M | ||
| Q2 24 | $53.9M | $31.1M | ||
| Q1 24 | $50.8M | $715.0K |
| Q4 25 | $-1.9M | — | ||
| Q3 25 | $-566.0K | $-91.3M | ||
| Q2 25 | $-261.0K | $-111.7M | ||
| Q1 25 | $-301.0K | $-116.2M | ||
| Q4 24 | $-206.0K | — | ||
| Q3 24 | $25.0K | $-83.5M | ||
| Q2 24 | $277.0K | $-97.1M | ||
| Q1 24 | $496.0K | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | -24.5% | -84.7% | ||
| Q3 25 | -7.4% | -140.7% | ||
| Q2 25 | -3.4% | -189.8% | ||
| Q1 25 | -3.8% | -245.8% | ||
| Q4 24 | -2.4% | -117.5% | ||
| Q3 24 | 0.2% | -152.1% | ||
| Q2 24 | 3.0% | -327.6% | ||
| Q1 24 | 0.2% | -16464.6% |
| Q4 25 | -3.8% | — | ||
| Q3 25 | -1.1% | -135.3% | ||
| Q2 25 | -0.5% | -186.2% | ||
| Q1 25 | -0.5% | -235.5% | ||
| Q4 24 | -0.4% | — | ||
| Q3 24 | 0.1% | -142.7% | ||
| Q2 24 | 0.5% | -312.2% | ||
| Q1 24 | 1.0% | -15800.8% |
| Q4 25 | $-0.37 | — | ||
| Q3 25 | $-0.11 | — | ||
| Q2 25 | $-0.05 | $-0.33 | ||
| Q1 25 | $-0.06 | $-0.36 | ||
| Q4 24 | $-0.05 | $-0.24 | ||
| Q3 24 | $0.01 | $-0.28 | ||
| Q2 24 | $0.06 | $-0.34 | ||
| Q1 24 | $0.11 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.8M | $297.0M |
| Total DebtLower is stronger | $13.6M | — |
| Stockholders' EquityBook value | $26.5M | $698.6M |
| Total Assets | $259.9M | $913.2M |
| Debt / EquityLower = less leverage | 0.51× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.8M | $297.0M | ||
| Q3 25 | $4.8M | $300.8M | ||
| Q2 25 | $9.6M | $301.2M | ||
| Q1 25 | $15.4M | $359.7M | ||
| Q4 24 | $23.7M | $323.8M | ||
| Q3 24 | $22.1M | $397.5M | ||
| Q2 24 | $29.2M | $412.5M | ||
| Q1 24 | $28.1M | $356.2M |
| Q4 25 | $13.6M | — | ||
| Q3 25 | $10.8M | — | ||
| Q2 25 | $7.8M | — | ||
| Q1 25 | $6.5M | — | ||
| Q4 24 | $6.9M | — | ||
| Q3 24 | $7.2M | — | ||
| Q2 24 | $7.6M | — | ||
| Q1 24 | $7.7M | — |
| Q4 25 | $26.5M | $698.6M | ||
| Q3 25 | $38.1M | $702.3M | ||
| Q2 25 | $41.0M | $698.5M | ||
| Q1 25 | $42.8M | $767.9M | ||
| Q4 24 | $44.1M | $710.4M | ||
| Q3 24 | $46.5M | $773.5M | ||
| Q2 24 | $45.9M | $768.5M | ||
| Q1 24 | $40.4M | $680.0M |
| Q4 25 | $259.9M | $913.2M | ||
| Q3 25 | $245.5M | $904.9M | ||
| Q2 25 | $246.3M | $907.4M | ||
| Q1 25 | $232.4M | $966.7M | ||
| Q4 24 | $240.4M | $910.4M | ||
| Q3 24 | $225.7M | $991.1M | ||
| Q2 24 | $218.8M | $964.3M | ||
| Q1 24 | $214.5M | $869.8M |
| Q4 25 | 0.51× | — | ||
| Q3 25 | 0.28× | — | ||
| Q2 25 | 0.19× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.16× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.17× | — | ||
| Q1 24 | 0.19× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-426.0K | $-52.6M |
| Free Cash FlowOCF − Capex | $-5.6M | $-61.9M |
| FCF MarginFCF / Revenue | -11.3% | -71.3% |
| Capex IntensityCapex / Revenue | 10.5% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-24.3M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-426.0K | $-52.6M | ||
| Q3 25 | $-1.6M | $-78.7M | ||
| Q2 25 | $3.3M | $-67.4M | ||
| Q1 25 | $2.2M | $-103.7M | ||
| Q4 24 | $7.3M | $-73.3M | ||
| Q3 24 | $1.4M | $-59.0M | ||
| Q2 24 | $5.6M | $-98.4M | ||
| Q1 24 | $3.5M | $-122.3M |
| Q4 25 | $-5.6M | $-61.9M | ||
| Q3 25 | $-7.7M | $-89.5M | ||
| Q2 25 | $-6.3M | $-74.9M | ||
| Q1 25 | $-4.7M | $-109.9M | ||
| Q4 24 | $165.0K | $-77.5M | ||
| Q3 24 | $-6.8M | $-61.3M | ||
| Q2 24 | $1.2M | $-98.9M | ||
| Q1 24 | $-586.0K | $-126.5M |
| Q4 25 | -11.3% | -71.3% | ||
| Q3 25 | -15.3% | -132.7% | ||
| Q2 25 | -11.5% | -124.9% | ||
| Q1 25 | -8.2% | -222.8% | ||
| Q4 24 | 0.3% | -105.1% | ||
| Q3 24 | -13.9% | -104.6% | ||
| Q2 24 | 2.3% | -317.9% | ||
| Q1 24 | -1.2% | -17685.3% |
| Q4 25 | 10.5% | 10.7% | ||
| Q3 25 | 12.0% | 16.1% | ||
| Q2 25 | 17.5% | 12.4% | ||
| Q1 25 | 11.9% | 12.6% | ||
| Q4 24 | 13.1% | 5.7% | ||
| Q3 24 | 16.9% | 3.9% | ||
| Q2 24 | 8.0% | 1.4% | ||
| Q1 24 | 8.1% | 583.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 57.96× | — | ||
| Q2 24 | 20.06× | — | ||
| Q1 24 | 7.08× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GENK
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
